- Home
- IFRX vs CRBP Comparison
IFRX vs CRBP Comparison
Compare IFRX & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- CRBP
- Stock Information
- Founded
- IFRX 2007
- CRBP 2009
- Country
- IFRX Germany
- CRBP United States
- Employees
- IFRX N/A
- CRBP N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- CRBP Health Care
- Exchange
- IFRX Nasdaq
- CRBP Nasdaq
- Market Cap
- IFRX 65.8M
- CRBP 73.4M
- IPO Year
- IFRX 2017
- CRBP N/A
- Fundamental
- Price
- IFRX $1.69
- CRBP $7.34
- Analyst Decision
- IFRX Strong Buy
- CRBP Strong Buy
- Analyst Count
- IFRX 4
- CRBP 10
- Target Price
- IFRX $8.50
- CRBP $53.56
- AVG Volume (30 Days)
- IFRX 262.5K
- CRBP 136.8K
- Earning Date
- IFRX 05-07-2025
- CRBP 05-06-2025
- Dividend Yield
- IFRX N/A
- CRBP N/A
- EPS Growth
- IFRX N/A
- CRBP N/A
- EPS
- IFRX N/A
- CRBP N/A
- Revenue
- IFRX $140,242.00
- CRBP N/A
- Revenue This Year
- IFRX $61.96
- CRBP N/A
- Revenue Next Year
- IFRX $80.59
- CRBP $150.00
- P/E Ratio
- IFRX N/A
- CRBP N/A
- Revenue Growth
- IFRX 30.90
- CRBP N/A
- 52 Week Low
- IFRX $0.82
- CRBP $4.64
- 52 Week High
- IFRX $2.82
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- IFRX 62.40
- CRBP 55.54
- Support Level
- IFRX $1.53
- CRBP $6.76
- Resistance Level
- IFRX $1.92
- CRBP $7.44
- Average True Range (ATR)
- IFRX 0.19
- CRBP 0.58
- MACD
- IFRX 0.02
- CRBP 0.00
- Stochastic Oscillator
- IFRX 74.59
- CRBP 62.94
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.